Attovia Therapeutics, Inc.
ATTO evidence brief
What we can confirm
- BioSniper Score:
- 4.0 / 10
- Market Cap:
- $1.08B
- Lead Asset:
- atto-1091 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for ATTO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ATTO
Attovia Therapeutics, Inc. (ATTO) is an early clinical-stage biopharmaceutical company founded in 2023, with no approved products and no product revenue, advancing three product candidates (ATTO-1310, ATTO-2306, ATTO-1091) through preclinical and early clinical development [sec · filed 2026-08-04].
Key risk: No approved products
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 4 clinical trials · 2 catalysts for Attovia Therapeutics, Inc..
Attovia Therapeutics, Inc. (ATTO) is an early clinical-stage biopharmaceutical company founded in 2023, with no approved products and no product revenue, advancing three product candidates (ATTO-1310, ATTO-2306, ATTO-1091) through preclinical and early clinical development [sec · filed 2026-08-04].
- Attovia commenced operations in 2023 and has no products approved for commercial sale [sec · filed 2026-08-04].
- The company has never generated any product revenue and reported net income of -$20.7M for the period ended 2026-06-30 [sec].
- Cash and equivalents stood at $32.8M as of 2026-06-30 [sec].
- Three product candidates are in development: ATTO-1310, ATTO-2306, and ATTO-1091 [sec · filed 2026-08-04].
- A Phase 1 study of ATTO-1091 and a Phase 2 study of ATTO-1310 are scheduled to start in December 2026 [upcoming catalysts].
What works
- The company has identified three distinct product candidates (ATTO-1310, ATTO-2306, ATTO-1091) and is advancing them into clinical trials, indicating a structured pipeline [sec · filed 2026-08-04].
- Attovia has secured initial public offering proceeds, reflected in cash of $32.8M as of 2026-06-30, providing near-term operating capital [sec].
What to weigh
- Attovia has a limited operating history (since 2023), has not completed any clinical trials, and has no approved products, making evaluation of its business viability difficult [sec · filed 2026-08-04].
- The company has incurred significant operating losses since inception and expects to continue incurring losses for the foreseeable future; net income was -$20.7M for the period ended 2026-06-30 [sec].
- Even after the IPO, Attovia will require substantial additional capital to finance operations and may be forced to delay or reduce programs if unable to raise funds [sec · filed 2026-08-04].
From the filings
Quoted directly from source documents.
Attovia is an early-stage company with no approved products and no revenue.
“We commenced operations in 2023, have no products approved for commercial sale and have never generated any revenue.”
SEC filings · August 4, 2026
The company has three named product candidates.
“particularly as we advance our product candidates, ATTO-1310, ATTO-2306 and ATTO-1091”
SEC filings · August 4, 2026
Attovia expects expenses to increase substantially as it advances candidates.
“we expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance our product candidates”
SEC filings · August 4, 2026
The company has incurred significant operating losses since inception.
“We have incurred significant operating losses since our inception and have not generated any product revenue.”
SEC filings · August 4, 2026
Catalyst timeline
- 2026-12-14 · Phase1_Start — ATTO-1091 Phase 1 study — A Phase 1 multi-part SAD/MAD study assessing safety, tolerability, and PK of ATTO-1091 in healthy volunteers and ulcerative colitis patients.
- 2026-12-21 · Phase2_Start — ATTO-1310 Phase 2 study — A Phase 2 multicenter, randomized, double-blind, placebo-controlled study of ATTO-1310 for chronic pruritus of unknown origin.
Risks & what to watch (4)›
Key risks
- No approved products — Attovia has no products approved for commercial sale and has never generated product revenue [sec · filed 2026-08-04].
- Cash runway uncertainty — Cash of $32.8M as of 2026-06-30 may be insufficient to complete development without additional capital [sec].
- Clinical trial failure risk — Drug development is highly speculative; any candidate may fail to show adequate efficacy or safety [sec · filed 2026-08-04].
- Limited operating history — Founded in 2023, the company has a very short track record for investors to evaluate [sec · filed 2026-08-04].
What to watch
- Initiation and early data from the Phase 1 study of ATTO-1091 in healthy volunteers and ulcerative colitis patients, expected to start 2026-12-14 [upcoming catalysts].
- Initiation and enrollment progress of the Phase 2 study of ATTO-1310 for chronic pruritus of unknown origin, expected to start 2026-12-21 [upcoming catalysts].
- Cash burn rate and any subsequent financing rounds, given the $32.8M cash position as of 2026-06-30 [sec].
Sources: SEC filings · SEC MD&A · Generated September 30, 2026 · How we verify sources →
Run Attovia Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Attovia Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$21M
Lead: Phase 2
3 candidates
2 upcoming, next in ~62d
8 buys · 46 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Attovia Therapeutics, Inc.?
Attovia Therapeutics, Inc. (ATTO) is an early clinical-stage biopharmaceutical company founded in 2023, with no approved products and no product revenue, advancing three product candidates (ATTO-1310, ATTO-2306, ATTO-1091) through preclinical and early clinical development [sec · filed 2026-08-04].
What is Attovia Therapeutics, Inc.'s lead drug candidate?
Attovia Therapeutics, Inc.'s most advanced tracked candidate is atto-1091 (Phase 2) for Ulcerative Colitis (UC).
What is Attovia Therapeutics, Inc.'s next catalyst?
Attovia Therapeutics, Inc.'s next tracked catalyst is a Phase1_Start event — "Phase1_Start: A Phase 1, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis" — expected December 14, 2026.
Who is the CEO of Attovia Therapeutics, Inc.?
Mr. Tao Fu M.B.A., M.S. is the chief executive officer of Attovia Therapeutics, Inc. (ATTO).
Where is Attovia Therapeutics, Inc. headquartered?
Attovia Therapeutics, Inc. (ATTO) is headquartered in San Carlos, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.